Citations

Clear

1526 citation(s) found for "Sun, Bo".

Population‐level gene expression can repeatedly link genes to functions in maize
Torres‐Rodríguez, J. Vladimir , Li, Delin , Turkus, Jonathan , Newton, Linsey , Davis, J M , López‐Corona, Lina , Ali, Waqar , Sun, Guangchao , Mural, Ravi V. , Grzybowski, Marcin , Zamft, Bradley M., Thompson, Addie , Davis, Jensina , Grzybowski, Marcin W , Thompson, Addie M , Schnable, James C , Ali, Waqar

Mayo Clinic

The Plant Journal | May 30, 2024 | Volume: 119 | Issue: 2 | Pages: 844-860

10.1111/tpj.16801 | PMID 38812347 Get It

SUMMARY Transcriptome‐wide association studies (TWAS) can provide single gene resolution for candidate genes in plants, complementing genome‐wide association studies (GWAS) but efforts in plants have been met with, at best, mixed success. We generated expression data from 693 maize genotypes, measured in a common field experiment, sampled over a 2‐h period to minimize diurnal and environmental effects, using full‐length RNA‐seq to maximize the accurate estimation of transcript abundance. TWAS could identify roughly 10 times as many genes likely to play a role in flowering time regulation as GWAS conducted data from the same experiment. TWAS using mature leaf tissue identified known true‐positive flowering time genes known to act in the shoot apical meristem, and trait data from a new environment enabled the identification of additional flowering time genes without the need for new expression data. eQTL analysis of TWAS‐tagged genes identified at least one additional known maize flowering time gene through trans ‐eQTL interactions. Collectively these results suggest the gene expression resource described here can link genes to functions across different plant phenotypes expressed in a range of tissues and scored in different experiments.
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).
Ye, Hong , Campbell, Jordan D., Karuturi, Meghan , Morikawa, Aki , Kimmick, Gretchen , Oh, Sun Young , Clark, Amy S. , D’Assoro, Antonino B. , Haddad, Tufia C. , Giridhar, Karthik V. , Suman, Vera J. , Tang, Xiaojia , Mayer, Erica L. , Isaacs, Claudine , Park, Ben Ho , Bucheit, Leslie , Tsai, Jill , Ingle, James N. , Goetz, Matthew P. , Kalari, Krishna R.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 1037-1037

10.1200/jco.2024.42.16_suppl.1037 Get It

1037 Background: TBCRC041, a randomized phase 2 trial of alisertib (A) ± fulvestrant (F) in women with HR+/HER2- MBC demonstrated promising clinical activity for alisertib (1). Interrogation of baseline (PreC1) and end of cycle 1 (EOC1) cfDNA and CTCs may identify biomarkers associated with response to A±F. Methods: Plasma cfDNA was sequenced using the Guardant INFINITY platform, which includes genomic and methylated tumor fraction (mTF) analysis. Pathogenic variants were determined using publicly available databases and Mayo Clinic annotation pipelines. CTCs were identified as nucleated, EpCAM+/ cytokeratin+/ CD45- cells and assessed for ER/HER2 staining (RareCyte, Seattle). PFS was defined as the time from randomization to progression or death. EOC1-PFS differs from PFS as time starts at C2D1. Stratified log-rank tests and conditional Cox modeling were used to assess whether PFS or EOC1-PFS differed by mutations in ESR1 or PIK3CA, pre-CTC ≥ 5, or mTF>1%. Results: Of the 91 eligible pts, 84 progressed, and 73 were deceased. In the 86 pts with PreC1-cfDNA results, variants were identified in ESR1 (42; 48.8%), PIK3CA (36; 41.9%), AKT1 (7; 8.1%), PTEN(7; 8.1%), BRCA1 (4; 4.7%), and BRCA2 (7; 8.1%). Pts with a PIK3CAmut had significantly decreased PFS (HR 1.8; 95%CI: 1.1 -2.9, p=0.014) but not by ESR1mut status (p=0.583). PreC1 and EOC1-mTF were determined for 78 and 76 pts, respectively. PreC1-mTF was 0-1% in 21; 1.1-10.0% in 27; and 10.1-100% in 30. mTF levels remained between 0-1% in 17 pts fell to 0-1% in 11 pts, and was 0-1% in 5 pts without a preC1-mTF determination. PFS did not differ with respect to PreC1-mTF (p=0.210), but EOC1-PFS was worse in pts with mTF >1% (HR 3.0; 95%CI: 1.6 -5.2, p<0.001). PreC1 and EOC1-CTC were determined for 78 and 76 pts. 36 (46.2%) pts had a PreC1 CTC count ≥ 5. EOC1-CTC levels remained at (n=17) or increased to (n=1) ≥ 5 and was ≥ 5 in 2 pts without a preC1-CTC determination. EOC1-PFS was not significantly different for EOC1-CTC ≥ 5 (p=0.065), but was significantly decreased in pts with PreC1-CTC≥5 (HR=1.8; 95%CI: 1.1-3.0; p=0.018). Broader cfDNA NGS panel and CTC-derived ER/HER2 staining results will be presented at the meeting. Conclusions: Among patients receiving A±F, PFS varied based on the PIK3CAmutation status. cfDNA and CTC assessment PreC1 and EOC1 provided complementary information. Further validation in larger datasets is needed. 1. JAMA Oncol 2023;9:815. Clinical trial information: NCT02860000 .
PFKFB3 controls acinar IP3R-mediated Ca2+ overload to regulate acute pancreatitis severity
Chen, Shengchuan , Jin, Yuepeng , Liu, Siying , Liu, Zhu, Shi, Fengyu, Xie, Lifen, Guo, Panpan , Ergashev, Akmal , Yao, Haiping , Huang, Chaohao , Zhang, Baofu , Wu, Lijun, Sun, Hongwei , Chen, Siming , Yu, Zhengping , Tolosa, Ezequiel J. , Fernández-Zapico, Martín E. , Ma, Feng , Cannon, Andrew C, Zhang, Tan , Li, Liang , Shi, Fengyu, Guo, Panpan , Cannon, Andrew , Wu, Lijun, Chen, Siming, Shan, Yunfeng , Liu, Jianghuai , Chen, Gang

Mayo Clinic

JCI Insight | May 23, 2024 | Volume: 9 | Issue: 13 | Pages: No page available

10.1172/jci.insight.169481 | PMID 38781030 Get It

Acute pancreatitis (AP) is among the most common hospital gastrointestinal diagnoses; understanding the mechanisms underlying the severity of AP is critical for development of new treatment options for this disease. Here, we evaluate the biological function of phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in AP pathogenesis in 2 independent genetically engineered mouse models of AP. PFKFB3 was elevated in AP and severe AP (SAP), and KO of Pfkfb3 abrogated the severity of alcoholic SAP (FAEE-SAP). Using a combination of genetic, pharmacological, and molecular studies, we defined the interaction of PFKFB3 with inositol 1,4,5-trisphosphate receptor (IP3R) as a key event mediating this phenomenon. Further analysis demonstrated that the interaction between PFKFB3 and IP3R promotes FAEE-SAP severity by altering intracellular calcium homeostasis in acinar cells. Together, our results support a PFKFB3-driven mechanism controlling AP pathobiology and define this enzyme as a therapeutic target to ameliorate the severity of this condition.
RefAI: a GPT-powered retrieval-augmented generative tool for biomedical literature recommendation and summarization
Li, Yiming , Zhao, Jeff, Li, Manqi , Dang, Yifang , Li, Jianfu , Sun, Zenan , Hussein, Usama, Wen, Jianguo, Li, Shenduo , Hu, Xinyue , Yang, Daowei, Feng, Jingna , Li, Zehan , He, Jianping , Tao, Wei , Lou, Yanyan , Sun, Zenan , Abdelhameed, Ahmed M, Duan, Tiehang , Li, Fang , Tao, Cui , Dang, Yifang , Li, Yiming , Yu, Evan Y , Wen, Jianguo, Abdelhameed, Ahmed , Mai, Junhua , Yu, Yue , Li, Fang , Tao, Cui

Mayo Clinic

Journal of the American Medical Informatics Association | May 21, 2024 | Volume: 31 | Issue: 9 | Pages: 2030-2039

10.1093/jamia/ocae129 | PMID 38857454 Get It

Abstract Objectives Precise literature recommendation and summarization are crucial for biomedical professionals. While the latest iteration of generative pretrained transformer (GPT) incorporates 2 distinct modes—real-time search and pretrained model utilization—it encounters challenges in dealing with these tasks. Specifically, the real-time search can pinpoint some relevant articles but occasionally provides fabricated papers, whereas the pretrained model excels in generating well-structured summaries but struggles to cite specific sources. In response, this study introduces RefAI, an innovative retrieval-augmented generative tool designed to synergize the strengths of large language models (LLMs) while overcoming their limitations. Materials and Methods RefAI utilized PubMed for systematic literature retrieval, employed a novel multivariable algorithm for article recommendation, and leveraged GPT-4 turbo for summarization. Ten queries under 2 prevalent topics (“cancer immunotherapy and target therapy” and “LLMs in medicine”) were chosen as use cases and 3 established counterparts (ChatGPT-4, ScholarAI, and Gemini) as our baselines. The evaluation was conducted by 10 domain experts through standard statistical analyses for performance comparison. Results The overall performance of RefAI surpassed that of the baselines across 5 evaluated dimensions—relevance and quality for literature recommendation, accuracy, comprehensiveness, and reference integration for summarization, with the majority exhibiting statistically significant improvements (P-values &lt;.05). Discussion RefAI demonstrated substantial improvements in literature recommendation and summarization over existing tools, addressing issues like fabricated papers, metadata inaccuracies, restricted recommendations, and poor reference integration. Conclusion By augmenting LLM with external resources and a novel ranking algorithm, RefAI is uniquely capable of recommending high-quality literature and generating well-structured summaries, holding the potential to meet the critical needs of biomedical professionals in navigating and synthesizing vast amounts of scientific literature.
Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology
Jackson, Lauren , Woodruff, Bryan K. , Tremblay, Cécilia , Shill, Holly A. , Beach, Thomas G. , Serrano, Geidy E., Adler, Charles H. , Jackson, Lauren M , Adler, C H , Serrano, Geidy E.

Mayo Clinic

Movement Disorders Clinical Practice | May 16, 2024 | Volume: 11 | Issue: 7 | Pages: 874-878

10.1002/mdc3.14068 | PMID 38757351 Get It

AbstractBackgroundThe G2019S leucine‐rich repeat kinase 2 (LRRK2) gene mutation is an important and commonly found genetic determinant of Parkinson's disease (PD). The neuropathological findings associated with this mutation have thus far been varied but are most often associated with Lewy body (LB) pathology.ObjectiveDescribe a case of clinical Parkinson's disease with levodopa responsiveness found to have LRRK2 mutations and the absence of Lewy bodies.MethodWe present an 89‐year‐old man with a 10‐year history of slowly progressive parkinsonism suspected to be secondary to Parkinson's disease.ResultsNeuropathological evaluation revealed nigral degeneration without Lewy bodies or Lewy neurites, but there were frequent tau‐immunopositive neurites and astrocytes in the putamen and substantia nigra, neocortical glial tau positive astrocytes associated with aging‐related tau astrogliopathy (ARTAG), as well as neurofibrillary tangles, beta amyloid plaques, and amyloid angiopathy typical of advanced Alzheimer's disease. G2019S LRRK2 homozygous mutations were found.ConclusionThis case illustrates that levodopa‐responsive clinical PD caused by G2019S LRRK2 mutations can occur without Lewy bodies.
Abstract GS02-02: Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
Laws, Alison , Ferrucci, Massimo , Mrdutt, Mary M., Moo, Tracy‐Ann , Boyle, Marissa K., Cabero, Flávia Vidal, Cocco, Daniela , Flanagan, Meghan R. , Hlavin, Callie , Jelinska, Justyna, Kuerer, Henry M. , Küemmel, Sherko , Menes, Tehillah S. , Pislar, Nina , Ryu, Jai Min , Tausch, Christoph, Uğurlu, Mustafa Ümit , Bruele, Astrid Botty van den , Vorburger, Denise , Weiss, Anna, Wong, Stephanie M. , Woodward, Steven G. , Zhang, Jennifer Q. , Ziauddin, M. Firdos, Çakmak, Güldeniz Karadeniz , Beşe, Nuran , Kühn, Thorsten, King, Tari A. , Ditsch, Nina , Banys‐Paluchowski, Maggie , Morrow, Monica , Wong, Stephanie M , Montagna, Giacomo , Polidorio, Natália , Sevilimedu, Varadan , Barrio, Andrea V. , Boyle, Marissa K., Corsi, Fabio , Crown, Angelena , Gülçelik, Mehmet Ali , Karanlık, Hasan , Kesmodel, Susan B , Leo, Cornelia , Pilewskie, Melissa , Rocco, Nicola , Soares, Leonardo Ribeiro , Urban, Cicero A. , Wärnberg, Fredrik , Williams, Austin David , Sun, Susie X. , Boughey, Judy C. , Weber, William P.

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: GS02-02-GS02-02

10.1158/1538-7445.sabcs23-gs02-02 Get It

Abstract Background: In patients with micro- and macrometastases in the sentinel lymph node (SLN) after neoadjuvant chemotherapy (NAC), additional positive nodes are found in &gt;60% of cases and axillary lymph node dissection (ALND) is currently considered standard of care. The likelihood of finding additional positive lymph nodes in patients with residual isolated tumor cells (ITCs) is unknown, and the benefit of ALND is unclear. As a consequence, surgical management of the axilla in these patients is not standardized. We sought to evaluate how often additional positive lymph nodes are found, to determine factors associated with ALND, and to compare oncological outcomes in patients treated with and without ALND after identification of residual ITCs in the SLN. Methods: Data were collected from 42 centers: 20 in the Oncoplastic Breast Consortium (OPBC) and EUBREAST networks, and 22 in North and South America. We included patients with cT1-4 N0-3 breast cancer at diagnosis who underwent NAC followed by axillary staging with either SLN biopsy (SLNB) or targeted axillary dissection (TAD) and were found to have residual ITCs [ypN0(i+)]. Single-tracer mapping was allowed for cN0 patients, while dual mapping or TAD was required for cN+ cases. Axillary treatment included completion ALND and/or nodal radiotherapy (RT). Competing risk analysis was performed to assess the cumulative incidence rates of any axillary recurrence (AR), locoregional recurrence (LRR), and any invasive (locoregional or distant) recurrence. Five-year cumulative incidence rates were compared between patients who underwent ALND and those who did not using the Gray’s test. Type I error rate was set to 0.05 (α). Results: We included 412 patients treated with NAC followed by surgery from 01/2009-05/2022. 146 (35.4%) had completion ALND and 266 (64.6%%) did not. Median patient age was 48 years. The majority (57%) of patients had clinical T2 tumors, and 68% had biopsy-proven N1 disease. Most were HR+/HER2- (41%) or HER2+ (39%). Most patients (80%) received anthracycline and taxane-based chemotherapy regimens. Nodal RT was administered to 83% of patients. The median number of SLNs with ITCs was 1. Patients treated with ALND were more likely to have ITCs detected on frozen section (61% v 6.7%, p&lt; 0.001), to have N2/3 disease at presentation (15.1% v 5.6%, p=0.001) and to have LVI (40% v 26%, p=0.004) (Table 1). There was no significant trend over time in the proportion of patients undergoing completion ALND during the study period (p=0.5). In the ALND group, additional positive nodes were found in 43/146 (29.5%) of cases, and consisted of macrometastases in 11/146 (7.5%), micrometastases in 9/146 (6.2%), and ITCs in 23/146 (15.8%). 5-year rates of any AR, LRR, and any invasive recurrence in the entire cohort were 2.7% (95% CI 1.2-5.4), 2.8% (95% CI 1.2-5.4) and 16% (95% CI 11-21), respectively. There was no statistical difference between patients who underwent ALND and those who did not in any of the 3 endpoints (2.2% v 3.1%, p=0.6), (2.6% v 3.0%, p=0.4) and (14% v 18%, p=0.12), respectively. Conclusion: The likelihood of finding additional positive lymph nodes in patients with ITCs after NAC is lower than in patients with residual micro- and macrometastases, and in the majority of cases, they contain ITCs. Nodal recurrence after omission of ALND is rare in this population. Overall, these results do not support routine ALND in patients with residual ITCs. Table 1. Clinicopathological Features of the Study Cohort, Stratified by Type of Axillary Surgery Frequency (row percent) reported for categorical variables, and median (IQR) reported for continuous variables. SLNB sentinel lymph node biopsy; TAD targeted axillary dissection; SLNs sentinel lymph nodes; LNs lymph nodes; pCR pathologic complete response; ACT anthracycline and taxane; AC anthracycline; H Herceptin, HP, Herceptin and Perjeta; TC taxol (or Taxotere) and carboplatinum; LVI lymphovascular invasion; BCS breast-conserving surgery. ^ Applied to HER2- tumors only (n=252). ^^ Applies to HER2+ tumors only (n=160). # LVI was present on core biopsy or final pathology. * Applies to BCS patients only (n=175). ** Applies to mastectomy patients only (n=237). Citation Format: Giacomo Montagna, Alison Laws, Massimo Ferrucci, Mary Mrdutt, Natália Polidorio, Varadan Sevilimedu, Tracy-Ann Moo, Andrea Barrio, Marissa K. Boyle, Flavia Vidal Cabero, Daniela Cocco, Fabio Corsi, Angelena Crown, Meghan R. Flanagan, Mehmet Ali Gulcelik, Callie Hlavin, Justyna Jelinska, Hasan Karanlik, Susan Kesmodel, Henry Kuerer, Sherko Küemmel, Cornelia Leo, Tehillah Menes, Melissa Pilewskie, Nina Pislar, Nicola Rocco, Jai Min Ryu, Leonardo Soares, Christoph Tausch, M. Umit Ugurlu, CICERO URBAN, Astrid Botty van de Bruele, Denise Vorburger, Fredrik Wärnberg, Anna Weiss, Austin Williams, Stephanie Wong, Steven G. Woodward, Susie X. Sun, Jennifer Q. Zhang, M. Firdos Ziauddin, Guldeniz Karadeniz Cakmak, Nuran Bese, Thorsten Kühn, Judy Boughey, Tari King, Nina Ditsch, Maggie Banys-Paluchowski, Monica Morrow, Walter Weber. Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr GS02-02.
Longitudinal Progression of CT Emphysema Subtypes Using Density-based and Hidden Markov Measure Field-based Thresholds: The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Wysoczanski, Artur , Bowler, R.P., Cooper, Christopher B. , Menchaca, Martha , Ortega, Victor E. , Paine, Robert , Woodruff, Prescott G. , Laine, Andrew F. , Angelini, Elsa D. , Hermann, E.A. , Dransfield, Mark T. , Han, MeiLan King , Hoffman, Eric A. , Krishnan, Jerry A , Menchaca, M.G., Ohar, Jill , Smith, Benjamin M. , Sun, Yuan‐Wan , Barr, R. Graham

Mayo Clinic

D15. MACHINE LEARNING AND LARGE COHORT STUDIES TO UNDERSTAND EXPOSURE-RELATED LUNG DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6928-A6928

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6928 Get It

Association of Pre-pandemic High Attenuation Areas on Lung CT and COVID-19 Hospitalization and Death: The C4R Study
Kim, J. , Balte, P., Sun, Yifei , Smith, B.M. , Podolanczuk, A., Lee, J.S., Washko, G.R., Hunninghake, G.M., Regan, E.A., Woodruff, P., Ortega, Victor E. , Lynch, David A. , Laine, Andrew F. , Hoffman, E.A., Oelsner, E., Hermann, E.A. , Schwartz, David A. , Stukovsky, Karen Hinckley , Make, Barry J. , Hoffman, E.A., Barr, R. Graham

Mayo Clinic

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6814-A6814

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6814 Get It